New 'Pan-KRAS' drug enters human testing for multiple Hard-to-Treat cancers
NCT ID NCT06607185
Summary
This is an early-stage trial to test the safety and determine the right dose of a new experimental drug called LY4066434. The drug is designed to block a common cancer-driving protein called KRAS in people with advanced solid tumors, including pancreatic, lung, and colorectal cancers. The study will give the drug alone and in combination with other treatments to about 750 participants over approximately five years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asklepios Kliniken Hamburg GmbH - Asklepios Klinik Altona
Hamburg, 22763, Germany
-
Cancer Institute & Hospital, Chinese Academy of Medical Sciences
Beijing, 100021, China
-
Cancer Institute Hospital of JFCR
Tokyo, 135-8550, Japan
-
Centre Leon Berard
Lyon, 69373, France
-
Centro Ricerche Cliniche di Verona s.r.l.
Verona, 37134, Italy
-
Charite Universitaetsmedizin Berlin
Berlin, 10117, Germany
-
City of Hope
Duarte, California, 91010, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Cliniques universitaires Saint-Luc
Brussels, 1200, Belgium
-
Columbia University
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Henry Ford Health System
Detriot, Michigan, 48202, United States
-
Hospital General Universitario Gregorio Maranon
Madrid, 28007, Spain
-
Hospital Regional Universitario de Malaga
Málaga, 29010, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital del Mar
Barcelona, 08003, Spain
-
Indiana University (IU)
Indianapolis, Indiana, 46202, United States
-
Institut Catala d'Oncologia - L'Hospitalet
Barcelona, 08908, Spain
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Krankenhaus Nordwest GmbH
Frankfurt, 60488, Germany
-
Kyoto University Hospital
Kyoto, 606-8507, Japan
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic - Rochester
Rochester, Minnesota, 55905, United States
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, 277-8577, Japan
-
National Taiwan University Hospital
Taipei, 10016, Taiwan
-
National Taiwan University Hospital Hsin-Chu Branch
Hsinchu, 300195, Taiwan
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
SLK-Kliniken Heilbronn GmBH
Heilbronn, 74078, Germany
-
Sarah Cannon Research Institute/SCRI
Nashville, Tennessee, 37203, United States
-
Shandong Province Tumor Hospital
Jinan, 250117, China
-
Shanghai East Hospital, Tongji University
Shanghai, 0200120, China
-
Shizuoka Cancer Center
Shizuoka, 411-8777, Japan
-
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics (START) Midwest
Grand Rapids, Michigan, 49546, United States
-
Swedish Cancer Institute (SCI)
Seattle, Washington, 98104, United States
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, 310006, China
-
The University of Chicago Medical Center (UCMC)
Chicago, Illinois, 60637, United States
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, 300060, China
-
UZ Gent
Ghent, 9000, Belgium
-
Universitaetsklinikum Wuerzburg
Würzburg, 97080, Germany
-
Universite Libre de Bruxelles (ULB) - Institut Jules Bordet
Brussels, 1070, Belgium
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of California, Los Angeles (UCLA)
Los Angeles, California, 90025, United States
-
University of Colorado Denver
Denver, Colorado, 80220, United States
-
University of Oklahoma - Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Texas Southwestern
Dallas, Texas, 75244, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
Yale University School of Medicine - Yale Cancer Center
New Haven, Connecticut, 06520-8028, United States
Conditions
Explore the condition pages connected to this study.